Every 8-K that Bausch + Lomb Corporation (BLCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BLCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLCO filings page.
Bausch + Lomb Corporation (BLCO) announced CEO and director Brent Saunders will depart effective October 12, 2026, and board chairman Thomas J. Appio will become interim CEO on that date. Appio will continue as CEO of parent Bausch Health Companies Inc. Saunders’ departure was mutually agreed and was not due to a dispute or disagreement over the company’s operations, policies or practices.
Under the separation agreement, Saunders is to receive a $75.5 million aggregate lump-sum cash payment and attorneys’ fee reimbursement up to $50,000; payment is contingent on his executing and not revoking a waiver and general release. He remains eligible for group health plan participation for two years. All outstanding equity and equity-based awards were forfeited and cancelled upon entering the agreement, and he is not entitled to further departure-related compensation or severance. He will provide reasonable transition assistance for 90 days after the separation date, with reasonable out-of-pocket expenses reimbursed.
Bausch + Lomb expects to raise full-year 2026 guidance for adjusted EBITDA excluding Acquired IPR&D, a non-GAAP measure, based on preliminary third-quarter results. It will provide additional details when it reports third-quarter results on October 28; the preliminary results remain subject to quarter-end closing and review procedures.
Bausch + Lomb Corporation reports updates to its board leadership and committee assignments effective August 10, 2026. Thomas J. Appio has succeeded Brent Saunders as Chairman of the Board, while Mr. Saunders continues to serve as a director. The board has also appointed Laurence Paul, M.D. as Lead Independent Director.
On the same date, Robert Chersi joined the Audit and Risk Committee and the Talent and Compensation Committee. Dr. Paul joined the Nominating and Corporate Governance Committee and the Science and Technology Committee. John A. Paulson was named chair of the Nominating and Corporate Governance Committee, Eduardo Alfonso, M.D. as chair of the Science and Technology Committee, and Barbara Trebbi as chair of the Talent and Compensation Committee.
Bausch + Lomb Corporation refreshed its board at the request of controlling shareholder Bausch Health Companies, appointing Thomas J. Appio, Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi on August 5, 2026, to replace four resigning directors whose departures were not due to disagreements.
The company agreed to prorated cash compensation and accelerated full vesting of outstanding and unvested restricted stock units from the 2026 annual grants for the departing directors, and entered into a one-year consulting agreement with former director Thomas W. Ross, Sr. that pays $400,000 in four quarterly installments, terminable on notice or for cause.
For the quarter ended June 30, 2026, revenue was $1.394 billion, up 9% year over year on a reported basis and 8% in constant currency. Net cash provided by operating activities increased from $32 million in the first quarter to $153 million, and adjusted cash flow from operations rose from $45 million to $161 million. The company reaffirmed 2026 guidance for revenue of $5.440–$5.540 billion and Adjusted EBITDA excluding Acquired IPR&D of $1.025–$1.075 billion.
Bausch + Lomb Corporation reported second‑quarter 2026 revenue of $1.394 billion, up 9% year over year, or 8% on a constant‑currency basis, with growth across Vision Care, Surgical and Pharmaceuticals. Operating income was $83 million versus an $11 million loss, while GAAP net loss narrowed to $14 million. Adjusted net income was $55 million and Adjusted EBITDA reached $241 million; GAAP EPS improved to ($0.04) and Adjusted EPS rose to $0.15. Cash flow from operations increased to $153 million.
The company raised full‑year 2026 guidance, targeting revenue of $5.440–$5.540 billion and Adjusted EBITDA excluding Acquired IPR&D of $1.025–$1.075 billion, reflecting continued strong performance, partly offset by slightly lower expected foreign‑exchange tailwinds. A pivotal study of the enVista Beyond investigational IOL met several co‑primary endpoints and showed a favorable safety profile, though it narrowly missed certain predefined performance targets.
Bausch + Lomb Corporation reported the results of its Annual Meeting of Shareholders held on May 20, 2026. Shareholders elected ten directors, including Eduardo Alfonso and Brenton L. Saunders, with each nominee receiving over 331 million votes in favor and around 4.2 to 4.3 million votes against, plus 11.45 million broker non-votes.
Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 328,089,056 votes for, 832,221 against, 6,896,414 abstentions and 11,452,072 broker non-votes. In addition, shareholders appointed PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm until the close of the 2027 annual meeting, with 343,283,263 votes for and 3,986,500 votes withheld.
Bausch + Lomb reported solid first-quarter 2026 growth and raised its full-year outlook. Revenue reached $1.244 billion, up 9% from the first quarter of 2025, or 6% on a constant currency basis, driven by all three segments.
Vision Care revenue grew to $711 million, Surgical to $228 million, and Pharmaceuticals to $305 million, with Pharmaceuticals up 14% and led by strong MIEBO and XIIDRA sales. Operating results improved markedly, shifting from an operating loss of $83 million to operating income of $33 million.
The company still posted a GAAP net loss of $71 million, but adjusted net income was $19 million and cash flow from operations turned positive at $32 million. Adjusted EBITDA rose to $189 million, or $200 million excluding acquired IPR&D, prompting higher 2026 revenue and adjusted EBITDA guidance.
Bausch + Lomb reported solid growth for 2025 but remained unprofitable. Fourth-quarter revenue reached $1.405 billion, up 10% year over year, with full-year revenue of $5.101 billion, up 6%. All three segments – Vision Care, Surgical and Pharmaceuticals – grew mid- to high-single digits for the year.
Despite this, the company posted a Q4 GAAP net loss of $58 million and a full-year net loss of $360 million. Profitability looked stronger on a non-GAAP basis: Q4 adjusted EBITDA rose to $326 million and full-year adjusted EBITDA was $858 million. Management guided 2026 revenue to $5.375–$5.475 billion with $1.0–$1.05 billion in adjusted EBITDA excluding acquired IPR&D, implying continued growth and margin focus.
Bausch + Lomb Corporation amended its existing credit agreement by arranging a new $2,802,125,000 tranche of term loans maturing in 2031, called the Replacement Term Loans. The proceeds were used to refinance its outstanding term B loans due 2031 and term B loans due 2028, effectively extending the earlier 2028 maturity to 2031.
The Replacement Term Loans amortize at 1.00% per year, with the first installment due on June 30, 2026. The applicable margin is 3.75% per year for loans referencing term SOFR and 2.75% per year for loans referencing the alternate base rate, representing margin reductions of 0.50% and 0.25%, respectively, compared with the prior term loans.
Bausch + Lomb Corporation filed an amended current report to update board committee assignments for two recently appointed directors. The company had previously disclosed that Eduardo C. Alfonso, MD, and Steven H. Collis would join the board effective January 1, 2026.
The amendment states that, effective January 1, 2026, Dr. Alfonso will serve on the Science and Technology Committee and Mr. Collis will serve on the Talent and Compensation Committee. These changes clarify how the new directors will participate in the company’s governance structure.
Bausch + Lomb Corporation announced that it has appointed Eduardo C. Alfonso, MD, and Steven H. Collis to its board of directors, effective January 1, 2026. They are filling vacancies created by the departures of Brett Icahn and Gary Hu from the board in August 2025.
The board determined that both new directors are independent under New York Stock Exchange and Toronto Stock Exchange rules and the company’s corporate governance guidelines. They have not yet been appointed to any board committees, will receive compensation under the standard Non-Employee Directors Compensation Policy, and have entered into the company’s standard director indemnification agreements. The company states there are no special arrangements or related-party transactions involving either new director that require disclosure.
Bausch + Lomb Corporation is refinancing part of its debt by allocating a new $2,802,125,000 tranche of term B loans, called the Replacement Term Loans. The company plans to use the proceeds to refinance its existing term B loans due 2031 and its term B loans due 2028.
The Replacement Term Loans are expected to carry a margin of 3.75% per year for loans tied to term SOFR and 2.75% per year for loans tied to the alternate base rate, reducing the margin by 0.50% on the 2031 loans and 0.25% on the 2028 loans. The new loans will mature on January 15, 2031, matching the current 2031 maturity and extending the 2028 loans’ maturity to that date. The company expects the refinancing to close in the first quarter of 2026 but notes there is no assurance it will be completed on these terms or at all.
Bausch + Lomb furnished an update tied to its Investor Day on November 13, 2025. The company announced that the event will cover three-year financial targets, details on pipeline products, and a re-affirmation of previously announced guidance for the fiscal year ending December 31, 2025.
A press release and a slide presentation were posted to the company’s website and furnished as Exhibits 99.1 and 99.2. A webcast and replay are available on the Investor Relations section of the site. The materials are being furnished under Regulation FD and are not deemed filed or incorporated by reference.
Bausch + Lomb Corporation furnished an 8-K announcing results of operations for the quarter ended September 30, 2025. The detailed financial information is provided in a press release attached as Exhibit 99.1.
The Item 2.02 information is being furnished and is not deemed filed under the Exchange Act, and it is not incorporated by reference into Securities Act filings. The company’s common shares trade as BLCO on the NYSE and Toronto Stock Exchange.
Bausch + Lomb Corporation reported that its Amended and Restated Director Appointment and Nomination Agreement with the Icahn Group terminated in accordance with its terms after the Icahn Group’s net long position in the common shares of Bausch + Lomb’s parent, Bausch Health Companies Inc., fell below a required threshold. The termination became effective on August 14, 2025.
On the same date, Brett Icahn and Gary Hu, who had joined the board in June 2022 as Icahn Group appointees, resigned from Bausch + Lomb’s board of directors. Mr. Hu also stepped down from the Audit and Risk Committee, the Talent and Compensation Committee, and the Science and Technology Committee. The company stated that their resignations did not result from any disagreement with Bausch + Lomb. On August 18, 2025, the company issued a press release summarizing these changes.
Bausch + Lomb (NYSE:BLCO) filed an 8-K detailing completion of a €675 million senior secured floating-rate note offering due 2031 and a comprehensive debt refinancing.
The company also executed a Third Amendment to its credit agreement, adding $2.325 billion of term loans maturing 2031 and replacing its $500 million revolver with a new $800 million facility maturing 2030.
Proceeds were used to fully repay the outstanding revolver and refinance all term A and B loans due 2027, effectively pushing major maturities out by four years and increasing available liquidity by $300 million.
The notes bear 3-month EURIBOR + 3.875%; term loans carry SOFR + 4.25% (base-rate +3.25%). The amendment raises the maximum first-lien net leverage covenant to 5.75×, stepping down over time, and retains customary covenants and events of default.
Bausch + Lomb announced significant debt refinancing activities on June 18, 2025. The company has priced an offering of €675 million senior secured floating rate notes due 2031, increased from the initially announced €600 million. The notes will be sold at 99.500% of principal value.
The company is also pursuing a refinancing package including a $2.325 billion new term B loan facility (increased from $2.2 billion) with Term SOFR + 4.25% interest rate, and a $800 million new revolving credit facility. These proceeds will be used to:
- Repay outstanding borrowings under existing revolving credit facility
- Refinance term A loans due 2027
- Refinance term B loans due 2027
- Pay related fees and expenses
The notes offering is expected to close on June 26, 2025, subject to customary conditions. The notes will be offered to qualified institutional buyers in the US under Rule 144A and internationally under Regulation S, with first-priority liens on assets securing the company's credit agreement.